{
  "retracted": false,
  "timestamp": 1496275200000,
  "updates": [
    {
      "timestamp": 1495740225788,
      "identifier": {
        "doi": "10.2337/dc17-er06c"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.2337/dc16-0917"
  },
  "journal": "Diabetes Care",
  "publisher": "American Diabetes Association",
  "title": "Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026â€“2035"
}
